126 related articles for article (PubMed ID: 35396702)
1. Drug-Drug Interactions and Disease Status Are Associated With Irinotecan-Induced Hepatotoxicity: A Cross-Sectional Study in Shanghai.
Li J; Chen B; Xi WQ; Jia W; Zhang WX; Bian XL
J Clin Pharmacol; 2022 Sep; 62(9):1160-1169. PubMed ID: 35396702
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for erlotinib-induced hepatotoxicity: a retrospective follow-up study.
Kim MK; Yee J; Cho YS; Jang HW; Han JM; Gwak HS
BMC Cancer; 2018 Oct; 18(1):988. PubMed ID: 30326853
[TBL] [Abstract][Full Text] [Related]
3. Risk factors associated with the incidence and time to onset of lapatinib-induced hepatotoxicity.
Moon JY; Han JM; Seo I; Gwak HS
Breast Cancer Res Treat; 2019 Nov; 178(1):239-244. PubMed ID: 31372791
[TBL] [Abstract][Full Text] [Related]
4. Factors affecting high-grade hepatotoxicity of tyrosine kinase inhibitors in cancer patients: a multi-center observational study.
Han JM; Han HW; Yee J; Kim MK; Moon JY; Cho S; Jung D; Cho YS; Seo I; Kim JY; Gwak HS
Eur J Clin Pharmacol; 2020 Aug; 76(8):1183-1191. PubMed ID: 32444938
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for irinotecan-induced liver injury: a retrospective multicentre cross-sectional study in China.
Han J; Liu J; Yu Z; Huang R; Zhao L; Xu Y; Chen M; He G; Song Q; Li W; Zhang C
BMJ Open; 2023 Jun; 13(6):e069794. PubMed ID: 37349101
[TBL] [Abstract][Full Text] [Related]
6. Factors Influencing Imatinib-Induced Hepatotoxicity.
Han JM; Yee J; Cho YS; Gwak HS
Cancer Res Treat; 2020 Jan; 52(1):181-188. PubMed ID: 31291714
[TBL] [Abstract][Full Text] [Related]
7. Exploration of components and mechanisms of Polygoni Multiflori Radix-induced hepatotoxicity using siRNA -mediated CYP3A4 or UGT1A1 knockdown liver cells.
Hu YH; Li DK; Quan ZY; Wang CY; Zhou M; Sun ZX
J Ethnopharmacol; 2021 Apr; 270():113845. PubMed ID: 33485974
[TBL] [Abstract][Full Text] [Related]
8. Regorafenib induced severe toxic hepatitis: characterization and discussion.
Sacré A; Lanthier N; Dano H; Aydin S; Leggenhager D; Weber A; Dekairelle AF; De Cuyper A; Gala JL; Humblet Y; Sempoux C; Van den Eynde M
Liver Int; 2016 Nov; 36(11):1590-1594. PubMed ID: 27500989
[TBL] [Abstract][Full Text] [Related]
9. In vitro evaluation of hepatotoxic drugs in human hepatocytes from multiple donors: Identification of P450 activity as a potential risk factor for drug-induced liver injuries.
Utkarsh D; Loretz C; Li AP
Chem Biol Interact; 2016 Aug; 255():12-22. PubMed ID: 26718876
[TBL] [Abstract][Full Text] [Related]
10. Role of CYP3A in ethanol-mediated increases in acetaminophen hepatotoxicity.
Kostrubsky VE; Szakacs JG; Jeffery EH; Wood SG; Bement WJ; Wrighton SA; Sinclair PR; Sinclair JF
Toxicol Appl Pharmacol; 1997 Apr; 143(2):315-23. PubMed ID: 9144448
[TBL] [Abstract][Full Text] [Related]
11. Analysis of Risk Factors for Hepatotoxicity Induced by Immune Checkpoint Inhibitors.
Cho YA; Han JM; Kang SY; Kim DC; Youn YJ; Choi KH; Gwak HS
J Immunother; 2021 Jan; 44(1):16-21. PubMed ID: 33290362
[TBL] [Abstract][Full Text] [Related]
12. The role of cigarette smoking and liver enzymes polymorphisms in anti-tuberculosis drug-induced hepatotoxicity in Brazilian patients.
Zaverucha-do-Valle C; Monteiro SP; El-Jaick KB; Rosadas LA; Costa MJ; Quintana MS; de Castro L
Tuberculosis (Edinb); 2014 May; 94(3):299-305. PubMed ID: 24793319
[TBL] [Abstract][Full Text] [Related]
13. Impaired irinotecan biotransformation in hepatic microsomal fractions from patients with chronic liver disease.
d'Esposito F; Nebot N; Edwards RJ; Murray M
Br J Clin Pharmacol; 2010 Sep; 70(3):400-8. PubMed ID: 20716241
[TBL] [Abstract][Full Text] [Related]
14. Female-specific activation of pregnane X receptor mediates sex difference in fetal hepatotoxicity by prenatal monocrotaline exposure.
Xiang E; Guo Q; Dai YG; Sun XX; Liu J; Fan CP; Wang YQ; Qiu SK; Wang H; Guo Y
Toxicol Appl Pharmacol; 2020 Nov; 406():115137. PubMed ID: 32682830
[TBL] [Abstract][Full Text] [Related]
15. Exacerbation of acetaminophen hepatotoxicity by the anthelmentic drug fenbendazole.
Gardner CR; Mishin V; Laskin JD; Laskin DL
Toxicol Sci; 2012 Feb; 125(2):607-12. PubMed ID: 22048645
[TBL] [Abstract][Full Text] [Related]
16. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.
Mathijssen RH; de Jong FA; van Schaik RH; Lepper ER; Friberg LE; Rietveld T; de Bruijn P; Graveland WJ; Figg WD; Verweij J; Sparreboom A
J Natl Cancer Inst; 2004 Nov; 96(21):1585-92. PubMed ID: 15523087
[TBL] [Abstract][Full Text] [Related]
17. A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan.
van der Bol JM; Mathijssen RH; Creemers GJ; Planting AS; Loos WJ; Wiemer EA; Friberg LE; Verweij J; Sparreboom A; de Jong FA
Clin Cancer Res; 2010 Jan; 16(2):736-42. PubMed ID: 20068078
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive assessment of Cucurbitacin E related hepatotoxicity and drug-drug interactions involving CYP3A and P-glycoprotein.
Lu J; Zhang Y; Sun M; Liu M; Wang X
Phytomedicine; 2017 Mar; 26():1-10. PubMed ID: 28257659
[TBL] [Abstract][Full Text] [Related]
19. RAT CYP3A and CYP2B1/2 were not associated with nevirapine-induced hepatotoxicity.
Walubo A; Barr S; Abraham AM
Methods Find Exp Clin Pharmacol; 2006 Sep; 28(7):423-31. PubMed ID: 17003847
[TBL] [Abstract][Full Text] [Related]
20. Liver Toxicity Observed With Lorlatinib When Combined With Strong CYP3A Inducers: Evaluation of Cynomolgus Monkey as a Nonclinical Model for Assessing the Mechanism of Combinational Toxicity.
Hu W; Lettiere D; Tse S; Johnson TR; Biddle KE; Thibault S; Palazzi X; Chen J; Pithavala YK; Finkelstein M
Toxicol Sci; 2021 Aug; 182(2):183-194. PubMed ID: 34021354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
